Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2010

01.09.2010 | Epidemiology

TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects

verfasst von: Li-Xin Qiu, Lei Yao, Chen Mao, Bo Chen, Ping Zhan, Kai Xue, Jian Zhang, Hui Yuan, Xi-Chun Hu

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Published data on the association between TGFB1 L10P polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between them. A total of 30 studies including 20,401 cases and 27,416 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with TGFB1 10P allele when all studies were pooled into the meta-analysis (LP vs. LL: OR = 1.046, 95% CI = 1.003–1.090; dominant model: OR = 1.052, 95% CI = 1.012–1.095). In the subgroup analysis by ethnicity, statistically significantly elevated risk was found in Caucasians (dominant model: OR = 1.045, 95% CI = 1.001–1.091). When stratified by study design, statistically significantly elevated risk was found based on population-based studies (dominant model: OR = 1.076, 95% CI = 1.019–1.136). In conclusion, this meta-analysis suggests that the TGFB1 10P allele may be a low-penetrant risk factor for developing breast cancer. However, large sample and representative population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108CrossRefPubMed
2.
Zurück zum Zitat Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMed Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMed
3.
Zurück zum Zitat Fujii D, Brissenden JE, Derynck R, Francke U (1986) Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet 12:281–288CrossRefPubMed Fujii D, Brissenden JE, Derynck R, Francke U (1986) Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet 12:281–288CrossRefPubMed
4.
Zurück zum Zitat Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8:93–97CrossRefPubMed Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8:93–97CrossRefPubMed
5.
Zurück zum Zitat Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y (2000) Association of a T29/C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101:2783–2787PubMed Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y (2000) Association of a T29/C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101:2783–2787PubMed
6.
Zurück zum Zitat Ziv E, Cauley J, Morin PA, Saiz R, Browner WS (2001) Association between the T29 → C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: the study of osteoporotic fractures. Jama 285:2859–2863CrossRefPubMed Ziv E, Cauley J, Morin PA, Saiz R, Browner WS (2001) Association between the T29 → C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: the study of osteoporotic fractures. Jama 285:2859–2863CrossRefPubMed
7.
Zurück zum Zitat Dunning AM, Ellis PD, McBride S (2003) A transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63:2610–2615PubMed Dunning AM, Ellis PD, McBride S (2003) A transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63:2610–2615PubMed
8.
Zurück zum Zitat Hishida A, Iwata H, Hamajima N (2003) Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer 10:63–69CrossRefPubMed Hishida A, Iwata H, Hamajima N (2003) Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer 10:63–69CrossRefPubMed
9.
Zurück zum Zitat Krippl P, Langsenlehner U, Renner W (2003) The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett 201:181–184CrossRefPubMed Krippl P, Langsenlehner U, Renner W (2003) The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett 201:181–184CrossRefPubMed
10.
Zurück zum Zitat Jin Q, Hemminki K, Grzybowska E (2004) Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer 112:94–99CrossRefPubMed Jin Q, Hemminki K, Grzybowska E (2004) Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer 112:94–99CrossRefPubMed
11.
Zurück zum Zitat Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE (2004) T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 13:412–415PubMed Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE (2004) T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 13:412–415PubMed
12.
Zurück zum Zitat Saha A, Gupta V, Bairwa NK, Malhotra D, Bamezai R (2004) Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5′-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet 31:37–42CrossRefPubMed Saha A, Gupta V, Bairwa NK, Malhotra D, Bamezai R (2004) Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5′-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet 31:37–42CrossRefPubMed
13.
Zurück zum Zitat Kaklamani VG, Baddi L, Liu J (2005) Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res 65:3454–3461PubMed Kaklamani VG, Baddi L, Liu J (2005) Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res 65:3454–3461PubMed
14.
Zurück zum Zitat Lee KM, Park SK, Hamajima N (2005) Genetic polymorphisms of TGF-beta1 and TNF-beta and breast cancer risk. Breast Cancer Res Treat 90:149–155CrossRefPubMed Lee KM, Park SK, Hamajima N (2005) Genetic polymorphisms of TGF-beta1 and TNF-beta and breast cancer risk. Breast Cancer Res Treat 90:149–155CrossRefPubMed
15.
Zurück zum Zitat Shin A, Shu XO, Cai Q, Gao YT, Zheng W (2005) Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev 14:1567–1570CrossRefPubMed Shin A, Shu XO, Cai Q, Gao YT, Zheng W (2005) Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev 14:1567–1570CrossRefPubMed
16.
Zurück zum Zitat Feigelson HS, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE (2006) Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 15:1236–1237CrossRefPubMed Feigelson HS, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE (2006) Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 15:1236–1237CrossRefPubMed
17.
Zurück zum Zitat Scola L, Vaglica M, Crivello A (2006) Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 1089:104–109CrossRefPubMed Scola L, Vaglica M, Crivello A (2006) Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 1089:104–109CrossRefPubMed
18.
Zurück zum Zitat Cox DG, Penney K, Guo Q (2007) TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses’ Health Study. BMC Cancer 7:175–181CrossRefPubMed Cox DG, Penney K, Guo Q (2007) TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses’ Health Study. BMC Cancer 7:175–181CrossRefPubMed
19.
Zurück zum Zitat Cox A, Dunning AM, Garcia-Closas M (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352–358CrossRefPubMed Cox A, Dunning AM, Garcia-Closas M (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352–358CrossRefPubMed
20.
Zurück zum Zitat Rajkumar T (2008) TGFb1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFb1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112:81–87CrossRefPubMed Rajkumar T (2008) TGFb1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFb1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112:81–87CrossRefPubMed
21.
Zurück zum Zitat Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRef Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRef
22.
Zurück zum Zitat Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
23.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed
24.
Zurück zum Zitat Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17 Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17
25.
Zurück zum Zitat Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed
26.
Zurück zum Zitat Taylor SJ, Tweedie RI (1998) Practical estimates of the effect of publication bias in meta- analysis. Australas Epidemiol 5:14–17 Taylor SJ, Tweedie RI (1998) Practical estimates of the effect of publication bias in meta- analysis. Australas Epidemiol 5:14–17
27.
Zurück zum Zitat Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506–520CrossRefPubMed Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506–520CrossRefPubMed
28.
Zurück zum Zitat Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117–129CrossRefPubMed Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117–129CrossRefPubMed
29.
Zurück zum Zitat Hirschhorn JN, Lohmueller K, Byrne E (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61CrossRefPubMed Hirschhorn JN, Lohmueller K, Byrne E (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61CrossRefPubMed
30.
Zurück zum Zitat Wacholder S, Chanock S, Garcia-Closas M (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442CrossRefPubMed Wacholder S, Chanock S, Garcia-Closas M (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442CrossRefPubMed
Metadaten
Titel
TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects
verfasst von
Li-Xin Qiu
Lei Yao
Chen Mao
Bo Chen
Ping Zhan
Kai Xue
Jian Zhang
Hui Yuan
Xi-Chun Hu
Publikationsdatum
01.09.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0781-7

Weitere Artikel der Ausgabe 2/2010

Breast Cancer Research and Treatment 2/2010 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.